Microbiota Evaluation of Patients With a Boston Type I Keratoprosthesis Treated With Topical 0.5% Moxifloxacin and 5% Povidone-Iodine

Página do item simplificado
dc.contributor.authorMagalhaes, Fernanda Pedreira [UNIFESP]
dc.contributor.authorNascimento, Heloisa Moraes do [UNIFESP]
dc.contributor.authorEcker, David J.
dc.contributor.authorSannes-Lowery, Kristin A.
dc.contributor.authorSampath, Rangarajan
dc.contributor.authorRosenblatt, Mark I.
dc.contributor.authorSousa, Luciene Barbosa de [UNIFESP]
dc.contributor.authorOliveira, Lauro Augusto de [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionIbis Biosci Inc
dc.contributor.institutionWeill Cornell Med Coll
dc.date.accessioned2016-01-24T14:31:32Z
dc.date.available2016-01-24T14:31:32Z
dc.date.issued2013-04-01
dc.description.abstractPurpose: To evaluate the efficacy of a prophylactic regimen of daily topical 0.5% moxifloxacin and 5% povidone-iodine (PI) in patients with Boston type I keratoprosthesis (KPro) and to assess the applicability of a novel molecular diagnostic technique to analyze the ocular surface microbiota in these patients.Methods: Ten patients had their inferior conjunctival fornix sampled for standard culture methods before the addition of topical 5% PI to the prophylactic regimen and were considered the control group (group 1). the inferior conjunctival fornix and the KPro-donor cornea interface of 10 patients treated with the mentioned prophylactic regimen were sampled and analyzed by standard culture methods and using a polymerase chain reaction/electrospray ionization mass spectrometry assay (group 2).Results: Samples from the inferior conjunctival fornix were positive for coagulase-negative staphylococcus in 3 patients and for Aerobasidium pullulans in 1 patient in group 1. the inferior conjunctival fornix and the KPro-donor cornea interface scrapings were positive for coagulase-negative staphylococcus in 2 patients and 1 patient, respectively, in group 2. No bacteria and fungi growth were detected in any patient from group 2 with the molecular diagnostic approach. None of the patients with culture-positive results developed keratitis or endophthalmitis during the study.Conclusions: Topical 0.5% moxifloxacin associated with topical 5% PI is an effective prophylactic regimen in patients with Boston type I KPro. the molecular diagnostic approach using serial polymerase chain reaction and mass spectrometry was comparable with standard microbiologic techniques as a surveillance tool in these patients.en
dc.description.affiliationUniversidade Federal de São Paulo, Dept Ophthalmol, BR-04023062 São Paulo, Brazil
dc.description.affiliationIbis Biosci Inc, Carlsbad, CA USA
dc.description.affiliationWeill Cornell Med Coll, Dept Ophthalmol, New York, NY USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Ophthalmol, BR-04023062 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipIbis Biosciences
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.format.extent407-411
dc.identifierhttp://dx.doi.org/10.1097/ICO.0b013e31824a8b9b
dc.identifier.citationCornea. Philadelphia: Lippincott Williams & Wilkins, v. 32, n. 4, p. 407-411, 2013.
dc.identifier.doi10.1097/ICO.0b013e31824a8b9b
dc.identifier.issn0277-3740
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/36181
dc.identifier.wosWOS:000315999500016
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofCornea
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectkeratoprosthesisen
dc.subjectpolymerase chain reactionen
dc.subjectkeratitisen
dc.titleMicrobiota Evaluation of Patients With a Boston Type I Keratoprosthesis Treated With Topical 0.5% Moxifloxacin and 5% Povidone-Iodineen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral